Sulphasalazine therapy in rheumatoid arthritis: qualitative changes in lymphocytes and correlation with clinical response.
Clinical and immunological parameters in 14 patients with rheumatoid arthritis (RA) receiving sulphasalazine (SASP) were evaluated, to determine whether their clinical response was reflected by any quantitative changes in their peripheral blood lymphocytes after 12 weeks. Whilst disease activity markers fell significantly, no such changes were noted in the percentage or absolute numbers of lymphocytes or their subsets. The lymphocytes of a further 21 patients before and after receiving SASP for 12 weeks were then studied qualitatively. The suppression mediated by in vitro SASP on ex vivo PHA stimulated lymphocytes showed a decrease at 12 weeks. This change was more marked and reached statistical significance only in those patients who showed a good clinical response. It is postulated that this may in some way be related to expression of activation markers and concomitant SASP binding.
Leicester Royal Infirmary.
A
A
Samanta
C
C
Webb
K A
KA
Grindulis
J
J
Fleming
P J
PJ
Sheldon
D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001809:Blood Viscosity; D002097:C-Reactive Protein / Q000032:analysis; D006801:Humans; D008137:Longitudinal Studies; D008213:Lymphocyte Activation / Q000187:drug effects; D012460:Sulfasalazine / Q000627:therapeutic use*
D012460:Sulfasalazine; D002097:C-Reactive Protein